Olema Pharmaceuticals (NASDAQ: OLMA) CLO nets 40,000-share stock sale

Rhea-AI Filing Summary

Olema Pharmaceuticals’ chief legal officer Mitchell Shawnte reported option exercises and related stock sales. On March 3–4, 2026, she exercised options for a total of 40,000 shares of common stock at $4.37 per share and sold 40,000 shares in open-market transactions at weighted average prices around the mid‑$20s. Following these trades, she reported 410,000 stock options outstanding and no directly held common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mitchell Shawnte

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN ST

(Street)

SAN FRANCISCO CA 94103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF LEGAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		M		15,000	A	$4.37	15,000	D
Common Stock	03/03/2026		S		15,000	D	$23.01(1)	0	D
Common Stock	03/04/2026		M		25,000	A	$4.37	25,000	D
Common Stock	03/04/2026		S		24,767	D	$24.25(2)	233	D
Comon Stock	03/04/2026		S		233	D	$24.69(3)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.37	03/03/2026		M			15,000	(4)	02/27/2035	Common Stock	15,000	$0	435,000	D
Stock Option (Right to Buy)	$4.37	03/04/2026		M			25,000	(4)	02/27/2035	Common Stock	25,000	$0	410,000	D

Explanation of Responses:

1. The weighted average sale price for the transaction reported was $23.01, and the range of prices were between $22.89 and $23.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

2. The weighted average sale price for the transaction reported was $24.25, and the range of prices were between $23.68 and $24.64. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

3. The weighted average sale price for the transaction reported was $24.69, and the range of prices were between $24.68 and $24.70. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

4. 25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

	/s/ Shawnte Mitchell	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Mitchell Shawnte report in the latest Olema (OLMA) Form 4?

Mitchell Shawnte reported exercising stock options and selling common shares of Olema Pharmaceuticals. She exercised options for 40,000 shares at $4.37 and sold 40,000 shares in open-market trades at weighted average prices in the low‑to‑mid $20s.

How many Olema (OLMA) shares did CLO Mitchell Shawnte sell?

Mitchell Shawnte sold a total of 40,000 shares of Olema common stock. These were reported in several open‑market transactions on March 3–4, 2026, with sale prices including $23.01, $24.25, and $24.69 weighted average prices disclosed in the footnotes.

At what prices were Olema (OLMA) shares sold by Mitchell Shawnte?

The reported Olema share sales had weighted average prices of $23.01, $24.25, and $24.69. Footnotes note trading ranges from $22.89 to $24.70. Full breakdowns of shares sold at each individual price level are available upon request from the issuer or SEC staff.

What stock options did Mitchell Shawnte exercise in Olema (OLMA)?

She exercised Olema stock options labeled “Stock Option (Right to Buy)” for 40,000 shares of common stock at an exercise price of $4.37 per share. After these exercises, she reported holding 410,000 option shares as of March 4, 2026.

How many Olema (OLMA) shares does Mitchell Shawnte hold after these transactions?

After the reported transactions, Mitchell Shawnte reported holding no Olema common shares directly. Her derivative holdings show 410,000 stock option shares outstanding as of March 4, 2026, reflecting options that remain exercisable subject to their vesting schedule.

What is the vesting schedule for Mitchell Shawnte’s Olema (OLMA) stock options?

One option grant vests 25% on February 28, 2026, with 1/48 of the total shares vesting monthly thereafter. Continued vesting is subject to her continuous service with Olema through each applicable vesting date, as disclosed in the footnote.